PL366692A1 - Kompozycje immunogenne kwasu hialuronowego o niskiej masie cząsteczkowej oraz sposoby zapobiegania,leczenia i diagnozowania zakażeń i chorób powodowanych przez paciorkowce z grupy A i grupy C - Google Patents

Kompozycje immunogenne kwasu hialuronowego o niskiej masie cząsteczkowej oraz sposoby zapobiegania,leczenia i diagnozowania zakażeń i chorób powodowanych przez paciorkowce z grupy A i grupy C

Info

Publication number
PL366692A1
PL366692A1 PL02366692A PL36669202A PL366692A1 PL 366692 A1 PL366692 A1 PL 366692A1 PL 02366692 A PL02366692 A PL 02366692A PL 36669202 A PL36669202 A PL 36669202A PL 366692 A1 PL366692 A1 PL 366692A1
Authority
PL
Poland
Prior art keywords
molecular weight
low molecular
hyaluronic acid
weight hyaluronic
immunogenic conjugates
Prior art date
Application number
PL02366692A
Other languages
English (en)
Inventor
Francis Michon
Samuel Moore
Maryline Laude-Sharp
Milan Blake
Original Assignee
Baxter International Inc.
Baxter Healthcare S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter International Inc., Baxter Healthcare S.A. filed Critical Baxter International Inc.
Publication of PL366692A1 publication Critical patent/PL366692A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
PL02366692A 2001-05-11 2002-05-10 Kompozycje immunogenne kwasu hialuronowego o niskiej masie cząsteczkowej oraz sposoby zapobiegania,leczenia i diagnozowania zakażeń i chorób powodowanych przez paciorkowce z grupy A i grupy C PL366692A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/853,367 US20020192205A1 (en) 2001-05-11 2001-05-11 Immunogenic compositions of low molecular weight hyaluronic acid and methods to prevent, treat and diagnose infections and diseases caused by group A and group C streptococci

Publications (1)

Publication Number Publication Date
PL366692A1 true PL366692A1 (pl) 2005-02-07

Family

ID=25315838

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02366692A PL366692A1 (pl) 2001-05-11 2002-05-10 Kompozycje immunogenne kwasu hialuronowego o niskiej masie cząsteczkowej oraz sposoby zapobiegania,leczenia i diagnozowania zakażeń i chorób powodowanych przez paciorkowce z grupy A i grupy C

Country Status (15)

Country Link
US (1) US20020192205A1 (pl)
EP (1) EP1385554A2 (pl)
JP (1) JP2005508854A (pl)
KR (1) KR20030096369A (pl)
CN (1) CN1525869A (pl)
AR (1) AR034331A1 (pl)
BR (1) BR0209562A (pl)
CA (1) CA2446555A1 (pl)
CO (1) CO5550467A2 (pl)
EC (1) ECSP034888A (pl)
HU (1) HUP0400840A3 (pl)
MX (1) MXPA03010283A (pl)
PL (1) PL366692A1 (pl)
SK (1) SK15122003A3 (pl)
WO (1) WO2002092131A2 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2251699C1 (ru) * 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
JP4576583B2 (ja) * 2005-03-22 2010-11-10 キユーピー株式会社 ヒアルロン酸またはその塩、およびその製造方法、ならびにこれを含有する化粧料および食品組成物
US20070225484A1 (en) * 2006-03-25 2007-09-27 Framroze Bomi P Process for the Isolation and Stabilization of Low-Molecular Weight Aminoglycans from Waste Egg Shells
US8529951B1 (en) 2007-02-21 2013-09-10 Anand Ramamurthi Elastogenic cues and methods for using same
US9687559B2 (en) 2008-03-19 2017-06-27 The Board Of Regents Of The University Of Oklahoma Heparosan polymers and methods of making and using same for the enhancement of therapeutics
US9925209B2 (en) 2008-03-19 2018-03-27 The Board Of Regents Of The University Of Oklahoma Heparosan-polypeptide and heparosan-polynucleotide drug conjugates and methods of making and using same
EP2341941A4 (en) * 2008-09-09 2014-12-10 Univ Oklahoma HEPAROSANE POLYMERS AND METHODS OF MAKING AND USING THEM TO ENHANCE THERAPEUTIC COMPOUNDS
US11065323B2 (en) * 2008-10-27 2021-07-20 Glaxosmithkline Biologicals Sa Purification method
CN102010469B (zh) * 2010-10-22 2013-02-27 上海贝西生物科技有限公司 一种抗透明质酸单克隆抗体及其用途
CN104302670A (zh) 2012-02-07 2015-01-21 Phi生物医药股份有限公司 制造用于经皮给药的透明质酸-蛋白结合体的方法以及由该方法制造的用于经皮给药的透明质酸-蛋白结合体
CN104237500B (zh) * 2014-09-30 2016-09-28 博奥赛斯（天津）生物科技有限公司 一种透明质酸固相包被方法
WO2018175752A1 (en) 2017-03-22 2018-09-27 Genentech, Inc. Optimized antibody compositions for treatment of ocular disorders
IT201900022626A1 (it) 2019-12-02 2021-06-02 Ub Care S R L Metodo per la determinazione del contenuto di sodio ialuronato in un idrogel
CN115590774B (zh) * 2022-10-20 2024-05-03 珠海原妙医学科技股份有限公司 透明质酸脂质体组装体及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
JPH0912600A (ja) * 1995-06-22 1997-01-14 Shiseido Co Ltd ヒアルロン酸ナトリウムに対するモノクローナル抗体及びその製造方法
CN1272062A (zh) * 1997-07-17 2000-11-01 北美疫苗公司 含有b组脑膜炎球菌膜孔蛋白和流感嗜血菌多糖的免疫偶联物
CA2332455C (en) * 1998-06-01 2012-08-14 Chiron Corporation Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants

Also Published As

Publication number Publication date
MXPA03010283A (es) 2004-12-06
ECSP034888A (es) 2004-05-28
HUP0400840A3 (en) 2004-10-28
AR034331A1 (es) 2004-02-18
HUP0400840A2 (hu) 2004-07-28
WO2002092131A3 (en) 2003-03-20
BR0209562A (pt) 2004-03-30
JP2005508854A (ja) 2005-04-07
EP1385554A2 (en) 2004-02-04
CA2446555A1 (en) 2002-11-21
WO2002092131A2 (en) 2002-11-21
KR20030096369A (ko) 2003-12-24
CO5550467A2 (es) 2005-08-31
CN1525869A (zh) 2004-09-01
US20020192205A1 (en) 2002-12-19
SK15122003A3 (sk) 2004-10-05

Similar Documents

Publication Publication Date Title
PL366692A1 (pl) Kompozycje immunogenne kwasu hialuronowego o niskiej masie cząsteczkowej oraz sposoby zapobiegania,leczenia i diagnozowania zakażeń i chorób powodowanych przez paciorkowce z grupy A i grupy C
MXPA03007323A (es) Proteinas artificiales con inmunogenicidad reducida.
HK1083190A1 (en) Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
PT1361893E (pt) Anticorpos anti-rfce modificados com imunogenicidade reduzida
EP1404178A4 (en) MIXTURES OF INSULIN AND OLIGOMERIC DRUG CONJUGATES COMPRISING POLYALKYLENE GLYCOL, AND USES AND METHODS FOR PREPARING THE SAME
AU6357900A (en) Hyaluronic acid-protein conjugates, pharmaceutical compositions and related methods
ATE535602T1 (de) Modifiziertes insulin mit reduzierter immunogenität
AU2001272937A1 (en) Localized molecular and ionic transport to and from tissues
MY144231A (en) Aß IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME
AU2002365360A1 (en) Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same
WO2005084303A3 (en) Interferon-beta polymer conjugates
AU2001255260A1 (en) Macroaggregated protein conjugates as oral genetic immunization delivery agents
SI1430082T1 (sl) Postopki za sintetiziranje konjugatov inzulinski polipeptid-oligomer in konjugati proinzulinski polipeptid-oligomer in postopki za njihovo sintetiziranje
UA82983C2 (ru) Полимерные коньюгаты найбластина и способы их использования
PL362375A1 (pl) Zmodyfikowana leptyna o obniżonej immunogeniczności
WO2005065382A8 (en) Polypeptides and immunogenic conjugates capable of inducing antibodies against pathogens, and uses thereof
AU2001285122A1 (en) Low molecular weight polyhydroxyalkanoate molding compositions
AU2002243314A1 (en) Immunogenic cancer peptides and uses thereof
PL362699A1 (pl) Zmodyfikowana protamina o obniżonej immunogeniczności
AU2002303259A1 (en) Peptides incorporating chemoselective functionalities
AU2001232854A1 (en) Free radical scavengers or promoters thereof as therapeutic adjuvants in pretermparturition
AU2001278323A1 (en) Modified sialic acid vaccines
AU2002318427A1 (en) N-fatty acid-amino acid conjugates and therapeutic uses
AU2002358565A1 (en) Thermoplastic compositions with enhanced mechanical properties
AU2002236160A1 (en) Immunogenic complex comprising ribosomes

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)